In silico studies, and molecular docking in particular, have been used to evaluate the potential interaction and potential effects of ginsenosides in targeting the BTK and p38 MAPK signaling pathways, suggesting potential benefits for RA [23,24]. The gene discussed is BTK; the disease is rheumatoid arthritis.